Biogen price to free cash flow BIIB

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026: 13.7×
10-year median: 13.1×
Against its 10-year history: 54th; percentile: 0 is its lowest day, 100 its highest
10-year range: 6.1× to 37.1×
Peer median: 24.3×

Biogen's price to free cash flow is 13.7× as of Oct 23, 2026.

That is above its ten-year median of 13.1×, close to the middle of its last ten years.

Over that time it ranged from 6.1× in Dec 2020 to 37.1× in Apr 2023.

The median for 10 large drugmakers of a similar size is 24.3×.

Price to free cash flow over time

median 13.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.7×	10.5×	14.4×
2025	11.3×	6.2×	11.8×
2024	11.3×	11.0×	35.2×
2023	35.3×	18.3×	37.1×
2022	18.2×	8.6×	20.0×
2021	16.5×	6.4×	20.7×
2020	6.2×	6.1×	9.1×
2019	8.5×	6.4×	13.5×
2018	11.7×	11.2×	20.5×
2017	17.8×	14.6×	22.3×
2016	18.3×	15.3×	21.6×
2015	22.4×	19.6×	42.1×
2014	30.9×	27.4×	42.3×
2013	37.5×	21.4×	39.3×
2012	21.7×	18.3×	24.1×
2011	17.8×	10.9×	21.0×
2010	12.3×	11.5×	15.1×

Against its peers

Companies in Drug Manufacturers - General nearest Biogen's size, closest first, today.

Company	Price to free cash flow
BIIBBiogen	13.7×
JAZZJazz Pharmaceuticals	8.7×
BMYBristol-Myers Squibb	11.0×
BMRNBiomarin Pharmaceutical	14.7×
CORTCorcept Therapeutics	86.8×
PTGXProtagonist Therapeutics	68.6×
TGTXTG Therapeutics	477×
PFEPfizer	15.6×
ALKSAlkermes plc.	33.0×
GILDGilead Sciences	14.9×
AMRXAmneal Pharmaceuticals	50.9×
Peer median	24.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Biogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.